Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
2.780
-0.150 (-5.12%)
Nov 13, 2026, 4:00 PM EST - Market closed
Adicet Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
102
Market Cap
29.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 24.99M | 15.26M | 156.83% |
| Dec 31, 2021 | 9.73M | -8.17M | -45.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
ACET News
- 3 days ago - Adicet Bio Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 8 days ago - Adicet Bio price target lowered to $55 from $90 at Guggenheim - TheFly
- 8 days ago - Adicet Bio reports Q3 EPS ($1.76), consensus ($1.58) - TheFly
- 8 days ago - Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates - Business Wire
- 8 days ago - Adicet Bio Earnings release: Q3 2026 - Filings
- 9 days ago - Adicet Bio Quarterly report: Q3 2026 - Filings
- 9 days ago - Adicet Bio Earnings release: Q3 2026 - Filings
- 14 days ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire